CircRNome-wide characterisation reveals the promoting role of circAATF in anti-PD-L1 immunotherapy of gallbladder carcinoma

Abstract

	•We present a comprehensive characterisation of circRNA landscape in gallbladder carcinoma (GBC).
	•CircAATF is positively associated with CD4+ T cell abundance and PD-L1 expression and is shown to promote PD-L1 treatment in mouse model.
	•CircAATF can elevate PD-L1 level through phosphorylated AKT and linear AATF, which upregulates PD-L1 by acting as a sponge of miR-142-5p.

Keywords

circular RNA / gallbladder carcinoma / immunotherapy / PD-L1 / tumour immunology

References

[1] NakamuraH, AraiY, TotokiY, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47: 1003-1010.

[2] SiegelRL, MillerKD, WagleNS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 17-48.

[3] RoaJC, García P, KapoorVK, MaithelSK, JavleM, KoshiolJ. Gallbladder cancer. Nat Rev Dis Primers. 2022; 8: 69.

[4] LiM, ZhangZ, LiX, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014; 46: 872-876.

[5] ZhaoY, YangM, FengJ, Wang X, LiuY. Advances in immunotherapy for biliary tract cancers. Chin Med J (Engl). 2024; 137: 524-532.

[6] FregaG, CossioFP, BanalesJM, et al. Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis. Cells. 2023; 12: 2098.

[7] LoJH, Agarwal R, GoffLW, HeumannTR. Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. Cancers (Basel). 2023; 15.

[8] LiS, HuZ, ZhaoY, Huang S, HeX. Transcriptome-wide analysis reveals the landscape of aberrant alternative splicing events in liver cancer. Hepatology. 2019; 69: 359-375.

[9] VoJN, Cieslik M, ZhangY, et al. The landscape of circular RNA in cancer. Cell. 2019; 176: 869-881. e813.

[10] XiangY, YeY, LouY, et al. Comprehensive characterization of alternative polyadenylation in human cancer. J Natl Cancer Inst. 2018; 110: 379-389.

[11] KristensenLS, Andersen MS, StagstedLVW, EbbesenKK, HansenTB, KjemsJ. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20: 675-691.

[12] LiS, HanL. Circular RNAs as promising biomarkers in cancer: detection, function, and beyond. Genome Med. 2019; 11: 15.

[13] LiuA, JiangB, SongC, et al. Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway. Med Comm (2020). 2023; 4: e282.

[14] WangZ, YangL, WuP, et al. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022; 21: 29.

[15] ConnVM, Chinnaiyan AM, ConnSJ. Circular RNA in cancer. Nat Rev Cancer. 2024.

[16] WangS, ZhangY, CaiQ, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression. Mol Cancer. 2019; 18: 145.

[17] HuangX, HeM, HuangS, et al. Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription. Mol Cancer. 2019; 18: 166.

[18] DubeU, Del-Aguila JL, LiZ, et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nat Neurosci. 2019; 22: 1903-1912.

[19] LiS, LiY, ChenB, et al. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res. 2018; 46: D106-D112.

[20] ChenS, HuangV, XuX, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019; 176: 831-843. e822.

[21] MaparaMY, SykesM. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004; 22: 1136-1151.

[22] PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264.

[23] LiuCX, LiX, NanF, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell. 2019; 177: 865-880. e821.

[24] ChenYG, ChenR, AhmadS, et al. N6-Methyladenosine modification controls circular RNA immunity. Mol Cell. 2019; 76: 96-109. e109.

[25] FangZ, JiangC, LiS. The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy. Front Immunol. 2020; 11: 617583.

[26] MemczakS, JensM, ElefsiniotiA, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495: 333-338.

[27] WestholmJO, MiuraP, OlsonS, et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. Cell Rep. 2014; 9: 1966-1980.

[28] GaoY, ZhangJ, ZhaoF. Circular RNA identification based on multiple seed matching. Brief Bioinform. 2018; 19: 803-810.

[29] ZhangXO, WangHB, ZhangY, Lu X, ChenLL, YangL. Complementary sequence-mediated exon circularization. Cell. 2014; 159: 134-147.

[30] QuinlanAR, HallIM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26: 841-842.

[31] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.

[32] HanzelmannS, Castelo R, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.

[33] LiberzonA, BirgerC, ThorvaldsdóttirH, GhandiM, Mesirov JP, TamayoP. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1: 417-425.

[34] HanksBA, Holtzhausen A, EvansKS, et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest. 2013; 123: 3925-3940.

[35] GatzaCE, Holtzhausen A, KirkbrideKC, et al. Type III TGF-beta receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia. 2011; 13: 758-770.

[36] LambertKE, HuangH, MythreyeK, Blobe GC. The type III transforming growth factor-beta receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 2011; 22: 1463-1472.

[37] KnelsonEH, Gaviglio AL, TewariAK, ArmstrongMB, Mythreye K, BlobeGC. Type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest. 2013; 123: 4786-4798.

[38] GatzaCE, OhSY, BlobeGC. Roles for the type III TGF-beta receptor in human cancer. Cell Signal. 2010; 22: 1163-1174.

[39] WangZ, ZhaoX, MaZ, LiuL, WangB, Li Y. Modulation on gallbladder carcinoma by TGF-beta1 via IGFBP-2. Cancer Biomark. 2018.

[40] WuZ, KeQ, JiangL, et al. TGF-beta1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m(6)A modification. Cell Death Dis. 2024; 15: 422.

[41] MaF, WangSH, CaiQ, et al. Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma. Biomed Pharmacother. 2017; 88: 863-869.

[42] IezziS, Fanciulli M. Discovering Che-1/AATF: a new attractive target for cancer therapy. Front Genet. 2015; 6: 141.

[43] TangD, ChenM, HuangX, et al. SRplot: a free online platform for data visualization and graphing. PLoS One. 2023; 18: e0294236.

[44] GiraldoNA, DrillE, SatravadaBA, et al. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022; 28: 5359-5367.

[45] de BitterTJJ, de Reuver PR, de Savornin LohmanEAJ, et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ Precis Oncol. 2022; 6: 83.

[46] PandeyA, Stawiski EW, DurinckS, et al. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat Commun. 2020; 11: 4225.

[47] HansenTB, VenoMT, DamgaardCK, Kjems J. Comparison of circular RNA prediction tools. Nucleic Acids Res. 2016; 44: e58.

[48] YangG, WangX, LiuB, et al. circ-BIRC6, a circularRNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis. Cell Cycle. 2019; 18: 976-989.

[49] YangH, ZhaoM, ZhaoL, Li P, DuanY, LiG. CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145. Cell Oncol (Dordr). 2020; 43: 477-488.

[50] ShaoT, PanYH, XiongXD. Circular RNA: an important player with multiple facets to regulate its parental gene expression. Mol Ther Nucleic Acids. 2021; 23: 369-376.

[51] JeckWR, Sorrentino JA, WangK, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19: 141-157.

[52] ChaoCW, ChanDC, KuoA, LederP. The mouse formin (Fmn) gene: abundant circular RNA transcripts and gene-targeted deletion analysis. Mol Med. 1998; 4: 614-628.

[53] GualandiF, Trabanelli C, RimessiP, et al. Multiple exon skipping and RNA circularisation contribute to the severe phenotypic expression of exon 5 dystrophin deletion. J Med Genet. 2003; 40: e100.

[54] CapassoA, LangJ, PittsTM, et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019; 7: 37.

[55] WangM, YaoLC, ChengM, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018; 32: 1537-1549.

[56] SarbassovDD, Guertin DA, AliSM, SabatiniDM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-1101.

[57] ZoncuR, EfeyanA, SabatiniDM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12: 21-35.

[58] LuoY, XuW, LiG, CuiW. Weighing in on mTOR complex 2 signaling: the expanding role in cell metabolism. Oxid Med Cell Longev. 2018; 2018: 7838647.

[59] LastwikaKJ, WilsonW 3rd, LiQK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016; 76: 227-238.

[60] ChenX, YangT, WangW, et al. Circular RNAs in immune responses and immune diseases. Theranostics. 2019; 9: 588-607.

[61] MaY, WangT, ZhangX, Wang P, LongF. The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications. Cell Death Dis. 2024; 15: 312.

[62] CaiJ, ChenZ, ZhangY, et al. CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m(6)A modification in hepatocellular carcinoma. Mol Ther Oncolytics. 2022; 24: 755-771.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.